- Home
- CEP vs CNTX Comparison
CEP vs CNTX Comparison
Compare CEP & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEP
- CNTX
- Stock Information
- Founded
- CEP 2020
- CNTX 2015
- Country
- CEP United States
- CNTX United States
- Employees
- CEP N/A
- CNTX N/A
- Industry
- CEP
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- CEP
- CNTX Health Care
- Exchange
- CEP NYSE
- CNTX Nasdaq
- Market Cap
- CEP 128.4M
- CNTX 149.6M
- IPO Year
- CEP 2024
- CNTX 2021
- Fundamental
- Price
- CEP $10.25
- CNTX $1.84
- Analyst Decision
- CEP
- CNTX Strong Buy
- Analyst Count
- CEP 0
- CNTX 3
- Target Price
- CEP N/A
- CNTX $6.83
- AVG Volume (30 Days)
- CEP 80.3K
- CNTX 318.3K
- Earning Date
- CEP 01-01-0001
- CNTX 11-06-2024
- Dividend Yield
- CEP N/A
- CNTX N/A
- EPS Growth
- CEP N/A
- CNTX N/A
- EPS
- CEP N/A
- CNTX N/A
- Revenue
- CEP N/A
- CNTX N/A
- Revenue This Year
- CEP N/A
- CNTX N/A
- Revenue Next Year
- CEP N/A
- CNTX N/A
- P/E Ratio
- CEP $615.97
- CNTX N/A
- Revenue Growth
- CEP N/A
- CNTX N/A
- 52 Week Low
- CEP $9.99
- CNTX $0.77
- 52 Week High
- CEP $10.28
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- CEP N/A
- CNTX 37.02
- Support Level
- CEP N/A
- CNTX $1.90
- Resistance Level
- CEP N/A
- CNTX $2.32
- Average True Range (ATR)
- CEP 0.00
- CNTX 0.14
- MACD
- CEP 0.00
- CNTX -0.04
- Stochastic Oscillator
- CEP 0.00
- CNTX 9.80
About CEP CANTOR EQUITY PARTNERS INC
Cantor Equity Partners Inc is a blank check company.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.